AGYAllergy TherapeuticsAGY info
$0.06info2.38%24h
Global rank15387
Market cap$38.05M
Change 7d7.50%
YTD Performance17100.00%
SP500 benchmarkOutperform
P/E-0.75
P/S0.48
Revenue$78.66M
Earnings-$56.85M
Dividend yield-
Main Sector
Healthcare

Allergy Therapeutics (AGY) Stock Overview

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Acarovac Plus, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

AGY Stock Information

Symbol
AGY
Address
Dominion WayWorthing, BN14 8SAUnited Kingdom
Founded
-
Trading hours
8:00 AM - 4:30 PM GMT
Website
https://www.allergytherapeutics.com
Country
🇬🇧 United Kingdom
Phone Number
44 1903 844 700

Allergy Therapeutics (AGY) Price Chart

-
Value:-

Allergy Therapeutics Overview: Key Details and Summary

Stock data
2023
Change
Price
$0.056760431379278484
N/A
Market Cap
$38.05M
N/A
Shares Outstanding
670.36M
4.26%
Employees
0
N/A
Valuation
2023
Change
P/E Ratio
-0.75
N/A
P/S Ratio
0.48
N/A
Earnings
2023
Change
Revenue
$78.66M
N/A
Earnings
-$56.85M
N/A
EPS
-0.0761
N/A
Earnings Yield
-1.34
N/A
Gross Margin
0.5579
N/A
Operating Margin
-0.5858
N/A
Net income margin
-0.7228
N/A
logo
Facebook Icon
Twitter Icon
Linkedin Icon
© 2024 Topstocks.org